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Many metabolic pathways, including lipid metabolism, are rewired in tumors to
support energy and biomass production and to allow adaptation to stressful en-
vironments. Neuroblastoma is the second deadliest solid tumor in children. Ge-
netic aberrations, as the amplification of theMYCN-oncogene, correlate strongly
with disease progression. Yet, there are only a fewmolecular targets successfully
exploited in the clinic. Here we show that inhibition of fatty acid synthesis led to
increased neural differentiation and reduced tumor burden in neuroblastoma
xenograft experiments independently of MYCN-status. This was accompanied
by reduced levels of the MYCN or c-MYC oncoproteins and activation of ERK
signaling. Importantly, the expression levels of genes involved in de novo fatty
acid synthesis showed prognostic value for neuroblastoma patients. Our findings
demonstrate that inhibition of de novo fatty acid synthesis is a promising pharma-
cological intervention strategy for the treatment of neuroblastoma indepen-
dently of MYCN-status.
INTRODUCTION
Neuroblastoma is the second most common solid tumor in children and accounts for up to 15% of cancer-
related deaths during childhood (Maris, 2010). It develops in the adrenal gland and the peripheral nervous
system from neural crest-derived precursors of the sympathetic nervous system. Neuroblastoma presenta-
tion is highly heterogeneous, both in terms of biological features and clinical response. According to the
International Neuroblastoma Staging System (INSS), patients are classified into five different stages (1–4
and 4S). Although stage 4 patients have the lowest survival probability, 4S tumors frequently undergo spon-
taneous regression and the children thus have a good prognosis (Ikeda et al., 2002). In addition, neuroblas-
toma patients are classified into three risk groups: high, medium, and low. Patients with low-risk neuroblas-
tomas undergo little or no clinical intervention, showing a survival probability of 90%–95%. In contrast,
high-risk patients have an event-free survival probability of less than 50% (Whittle et al., 2017), suffer tumor
recurrence and metastasis, and develop treatment resistance leading to a fatal outcome.
Amplification of MYCN is used as a diagnostic parameter to classify neuroblastoma patients into stages
and risk groups.MYCN-amplified neuroblastomas are always considered as high risk. In fact,MYCN ampli-
fication, occurring in around 25% of all primary neuroblastomas and in 30%–40% of all high-risk cases (Pugh
et al., 2013; Huang and Weiss, 2013), has since long been known to correlate to poor clinical outcome (Bro-
deur et al., 1984). Both MYCN and c-MYC belong to the MYC oncogene family. It has been shown that
MYCN promotes pluripotency and blocks differentiation pathways (Ruiz-Perez et al., 2017). Importantly, in-
duction of differentiation in neuroblastoma cells requires early MYCN expression (Guglielmi et al., 2014),
followed by downregulation (Huang and Weiss, 2013).
Although c-MYC is involved in the control of multiple metabolic processes, including lipid metabolism
(Eberlin et al., 2014; Edmunds et al., 2014; Morrish et al., 2010; Gouw et al., 2019; Carroll et al., 2018; Dejure
and Eilers, 2017), the role of MYCN in metabolism is less clear. It has been shown to drive increasediScience 24, 102128, February 19, 2021 ª 2021 The Author(s).





Articleglutathione biosynthesis (Carter et al., 2016) and the overexpression of the glutamine transporter ASCT2,
whose levels correlate to bad prognosis in neuroblastoma patients (Ren et al., 2015). MYCN overexpres-
sion, in cooperation withMondoA, led to increased levels of proteins involved in lipid metabolism, whereas
MYCN and MondoA inactivation was connected to reduced de novo fatty acid synthesis (Carroll et al.,
2015). MYCN drives changes in mitochondrial fusion, morphology, and function related to apoptosis resis-
tance and to metabolic processes (Casinelli et al., 2016; Zirath et al., 2013; Oliynyk et al., 2019). Our group
recently showed that MYCN promotes glycolysis, oxidative metabolism, and de novo glutamine synthesis.
Importantly, neuroblastoma highly relies on fatty acid oxidation for energy production, and inhibition of
b-oxidation leads to reduced growth of MYCN-amplified, but not of non-MYCN-amplified, cells and tu-
mors (Oliynyk et al., 2019).
Fatty acid synthesis occurs in the cytosol and involves multiple steps (Figure 1A). The two key enzymes
involved are acetyl-CoA carboxylase (ACACA) and fatty acid synthase (FASN). In the first step, ACACA syn-
thetizes malonyl-CoA from acetyl-CoA. Malonyl-CoA is further converted into palmitate by FASN. Palmi-
tate is subsequently elongated and desaturated by additional enzymes to produce all the other non-essen-
tial fatty acids (Nelson et al., 2017; Maier et al., 2010; Guillou et al., 2010). In the adult human, de novo fatty
acid synthesis occurs only in the liver, adipose tissue, and lactating mammary gland. However, virtually all
tumors reactivate this pathway, as well as other lipid synthesis pathways, in order to support increased pro-
liferation, as they require lipids both as membrane components and as signaling molecules involved in
stress response, cell survival, cell death, invasion, metastasis, and symbiotic relationships with the tumor
stroma (Santos and Schulze, 2012; Rohrig and Schulze, 2016; Snaebjornsson et al., 2020).
The work presented here sheds light onto the relevance of the de novo fatty acid synthesis for
neuroblastoma.RESULTS
Inhibition of de novo fatty acid synthesis reduces cell growth andMYC expression and results
in differentiation in neuroblastoma cells
To study the relevance of fatty acid synthesis for neuroblastoma biology, we inhibited this process with the
use of five small molecule inhibitors in a panel of MYCN-amplified (MNA) and non-MYCN-amplified
(NMNA) neuroblastoma cells (Table S1). Two of these inhibitors, TOFA and Soraphen A, target ACACA,
whereas the other three, Cerulenin, Orlistat, and UB006, target FASN (Figure 1A).
Inhibition of fatty acid synthesis resulted in reduced cell proliferation in all neuroblastoma cell lines tested
(Figure 1B). When comparing the effects of fatty acid synthesis inhibition in neuroblastoma cells and human
primary fibroblasts, we observed that all three neuroblastoma cell lines died at concentrations of UB006
equal to the IC50 of the fibroblasts (over 20 mM UB006) (Figure S1A). Western blot analysis showed
increased cleavage of poly ADP-ribose polymerase (PARP) after treatment with TOFA or Cerulenin, sug-
gesting that fatty synthesis inhibition results in apoptosis in neuroblastoma cells (Figure S1B). Cell cycle
analysis by flow cytometry showed that inhibition of both ACACA and FASN induced cell death as indi-
cated by an increase in the sub-G1 population and reduced number of cells in S/G2/M cell cycle phases
at different time points (Figure S1C). The decrease in cell proliferation and increased cell death was accom-
panied by reduced protein expression of MYCN (in MNA cells) or c-MYC (in NMNA cells) upon treatment
with all tested inhibitors (Figures 1C and S1D).
One striking effect of inhibition of de novo fatty acid synthesis in neuroblastoma cells was the induction of
differentiation as indicated by increased neurite outgrowth and expression of neural differentiation
markers. All tested inhibitors increased the protein expression of Tubulin B3 and the neurotrophic tyrosine
kinase receptor type 1 (TRKA) in SK-N-BE(2) and IMR-32 cells, whereas all inhibitors except Soraphen A led
to their expression in KCN-n69 cells (Figures 1D–1F). We analyzed the levels of additional markers of dif-
ferentiation in SK-N-BE(2) cells treated with TOFA, Cerulenin, or Orlistat using qPCR (Figure 1G). All treat-
ments reduced the expression of the gene encoding the neural stem cell marker SRY-box transcription fac-
tor 2 (SOX2) and increased the expression of the genes encoding the neural differentiation markers
neuropeptide Y (NPY), secretogranin 2 (SCG2), and thyroxine hydroxylase (TH). Importantly, inhibition of
fatty acid synthesis with TOFA or UB006 in two MYCN-amplified human-patient-derived xenograft
(PDX)-derived cell cultures (Persson et al., 2017) also induced neurite outgrowth, expression of the differ-
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Figure 1. Inhibition of de novo fatty acid synthesis reduces cell growth and MYC expression and induces differentiation in neuroblastoma cells,
related to Figure S1 and Table S1
(A) Fatty acid synthesis pathway and inhibitors used in this study. See main text for details. TCA cycle: tricarboxylic acid cycle; ACLY: ATP-citrate lyase;
ACACA: acetyl-CoA carboxylase; FASN; fatty acid synthase.
(B) Cell proliferation curves of the indicated MYCN-amplified (SK-N-BE(2), IMR-32, and KCN-n69) and non-MYCN-amplified (SH-SY5Y and SK-N-SH)
neuroblastoma cell lines as quantified by cell counting at the indicated time points. Data are presented as meanG SD of three independent experiments, %
of day 0.
(C) Western blot analysis of MYCN protein expression in the indicated cell lines and time points upon fatty acid synthesis inhibition.
D: DMSO; T: TOFA; C: Cerulenin; O: Orlistat; S: Soraphen A; U: UB006. a-tubulin or b-actin were used as loading controls as indicated.
(D) Immunofluorescence staining of SK-N-BE(2) cells treated for 7 days with vehicle or the indicated inhibitors. Blue: DAPI; green: Tubulin B3; red: SCG2.
Scale bar indicates 50 mm.
(E) Immunofluorescence staining of KCN-n69 cells treated for 7 days with vehicle or the indicated inhibitors. Blue: DAPI; green: Tubulin B3; red: SCG2. Scale
bar indicates 50 mm.
(F) Immunofluorescence staining of IMR-32 cells treated for 7 days with vehicle or the indicated inhibitors. Blue: DAPI; green: Tubulin B3; red: SCG2. Scale bar
indicates 100 mm.
(G) mRNA fold expression of the indicated genes in SK-N-BE(2) treated for 7 days with vehicle or the indicated inhibitors, as quantified by qPCR.
(H) Immunofluorescence staining of PDX-derived cell cultures, LU-NB-2 and LU-NB-3, treated for 7 days with vehicle or the indicated inhibitors. Blue: DAPI;
green: Tubulin B3; red: SCG2. Scale bar indicates 100 mm.
(I) Western blot analysis of SCG2 andMYCN protein expression in LU-NB-2 and LU-NB-3 after 7 days upon fatty acid synthesis inhibition. (D) DMSO; T: TOFA;
U: UB006. b-actin was used as loading control as indicated.
Data are presented as mean G SD of three independent experiments; statistical analysis: t test of each inhibitor compared with vehicle, with *, **, and ***




Articleaddition, TOFA, Cerulenin, and Orlistat increased protein expression of the neural differentiation marker
Tubulin B3 in SH-SY5Y and SK-N-SH cells (Figure S1E). In the case of SK-N-SH and SH-EP cells, which do not
undergo neural but glial differentiation, each of the treatments induced morphological changes and also
augmented the levels of vimentin (Figure S1E). All neuroblastoma cells tested, except KELLY and SK-N-AS,
showedmorphological changes indicative of increased differentiation (Figure S1F). Notably, SK-N-AS cells
do not differentiate upon treatment with the well-established differentiation agent all-trans retinoic acid
(ATRA) (Gaetano et al., 1991) (Figure S1G), whereas KELLY cells to our knowledge have not been described
to differentiate in any condition. Furthermore, we found increased expression of the differentiation marker
SCG2 in the ex vivo TH-MYCN tumor sphere model (Ribeiro et al., 2016) after inhibition of fatty acid syn-
thesis (Figures S1H and S1I).
Together our results show that inhibition of fatty acid synthesis in neuroblastoma cells leads to reduced
proliferation, increased cell death, lower levels of MYC(N) proteins, and induction of neural differentiation.Neural differentiation is a specific consequence of diminished fatty acid synthesis and lipid
withdrawal
To rule out the existence of off-target effects of the tested fatty acid synthesis inhibitors, we transfected
SK-N-BE(2) cells with negative control or specific anti-FASN siRNA, leading to a potent reduction of
both FASN protein and mRNA levels (Figure 2A). Already 72 h after transfection, the neuroblastoma
cells experienced a marked increase of expression levels of the differentiation markers SCG2 and
NPY at mRNA levels (Figure 2A). This was accompanied by prominent neurite outgrowth and increased
protein expression of the differentiation markers SCG2 and Tubulin B3 as shown by immunofluores-
cence (Figure 2B). These results indicate that reduced levels of FASN lead to the same phenotype as
upon inhibition of fatty acid synthesis with small compounds and shows that FASN downregulation is
even more potent in its ability to induce differentiation, as robust neurite outgrowth is observed after
only 3 days.
Next we analyzed if reduced availability of exogenous lipids could lead to induction of differentiation. As
shown in Figure 2C, incubation of SK-N-BE(2) cells in growth medium containing delipidized serum led to
robust neurite outgrowth and expression of the neural differentiation markers Tubulin B3 and SCG2,
together with reduced MYCN protein levels (Figure 2D). Similar to TOFA and Cerulenin, delipidized serum
also led to an increase in cleaved PARP (Figure S1D). We next assessed whether interfering with the pro-
duction of fatty acid-derived lipid species, such as phospholipids, had a similar impact on neuroblastoma
cells. To this end, we treated SK-N-BE(2) cells with CI-976, an inhibitor of lysophospholipid acyltransferase
(LPAT) and sterol O-acyltransferase (ACAT) (Figure S2A), which induced strong neural differentiation (Fig-
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Figure 2. Induction of differentiation is not a general response to nutrient starvation but a specific consequence
of diminished fatty acid synthesis and lipid withdrawal, related to Figure S2
(A) Upper row: FASN protein (left) and mRNA (right) levels in SK-N-BE(2) cells transfected for 72 h with negative control
siRNA or siRNA against FASN. Lower row: quantification of the mRNA expression levels of the differentiation markers
SCG2 and NPY in SK-N-BE(2) cells transfected for 72 h with negative control siRNA or siRNA against FASN, as quantified
by qPCR.
(B) Immunofluorescence staining of SK-N-BE(2) cells transfected for 72 h with negative control siRNA or siRNA targeting
FASN. Blue: DAPI; green: Tubulin B3; red: SCG2. Scale bar indicates 20 mm.
(C) Immunofluorescence staining of SK-N-BE(2) cells incubated for 7 days in complete or delipidized medium. Blue: DAPI;
green: Tubulin B3; red: SCG2. Scale bar indicates 20 mm.
(D) Western blot analysis of MYCN protein in SK-N-BE(2) cells upon incubation in complete or delipidized medium for
7 days.
(E) Immunofluorescence staining of SK-N-BE(2) cells treated for 7 days with vehicle or CI-976. Blue: DAPI; green: Tubulin
B3. Scale bar indicates 20 mm.
(F) Western blot analysis of MYCN protein in SK-N-BE(2) cells upon treatment with vehicle or CI-976 for 7 days.
(G) Immunofluorescence staining of SK-N-BE(2) cells incubated for 7 days in complete, low glucose or low glutamine
medium. Blue: DAPI; green: Tubulin B3; red: SCG2. Scale bar indicates 50 mm.
(H) Immunofluorescence staining of SK-N-BE(2) cells treated for 7 days with vehicle, TOFA, or Cerulenin G BSA/BSA-
bound oleate. Blue: DAPI; green: Tubulin B3. Scale bar indicates 20 mm.
Western blot and microscopic images are representative of at least three independent experiments. b-actin was used as
loading control in Western blots as indicated. qPCR data are presented as mean G SD of at least three independent




ArticleWewondered whether neuroblastoma cells would undergo differentiation as a consequence of any type of
nutrient starvation. To assess this, we incubated SK-N-BE(2) cells up to 7 days in growth medium with
reduced glucose (1 mM versus 7.7 mM) or reduced glutamine (0.25 mM versus 2 mM). However, neither
of these conditions resulted in morphological changes indicative of differentiation or in increased expres-
sion of the differentiation markers Tubulin B3 or SCG2 (Figure 2G).
To rule out the possibility that induction of differentiation upon inhibition of fatty acid synthesis could be a
side effect of the chemical inhibitors used, we performed a rescue experiment in which SK-N-BE(2) cells
were treated with TOFA or Cerulenin in combination with BSA or BSA-bound oleate. As shown in Figure 2H,
exogenous oleate completely prevented the induction of differentiation by TOFA and Cerulenin. In addi-
tion, oleate rescued MYCN levels at 72 h of treatment but not after 7 days (Figure S2B). Neuroblastoma
differentiation requires an initial increase in MYCN protein expression followed by a reduction (Guglielmi
et al., 2014). Exogenous oleate partially prevented MYCN downregulation by TOFA and Cerulenin during
the first days of treatment, and this might be enough to prevent differentiation induction even if MYCN
levels are reduced later.
We also examined the ability of fatty acid synthesis inhibitors to potentiate all-trans retinoic acid (ATRA)
induction of differentiation on NB cells. Morphologically, TOFA+ATRA- and Cerulenin+ATRA-treated cells
showed fewer cell bodies and longer neurites compared with control or single-agent-treated cells (Fig-
ure S2C). TOFA+ATRA-treated cells had increased levels of Tubulin B3, whereas treatment with
Cerulenin+ATRA increased the levels of SCG2 and further reduced the expression of MYCN, compared
with single treatments (Figure S2D).
Collectively, our results show that neuroblastoma cells undergo differentiation upon reduced lipid synthe-
sis or limited availability of lipids but not when subjected to restriction of other major nutrients such as
glucose and glutamine.Inhibition of fatty acid synthesis impacts cellular lipid composition as well as mitochondrial
morphology and function
We proceeded to evaluate the impact of MYCN levels on fatty acid metabolism in neuroblastoma cells. To
this end, we performed tracing experiments to follow the contribution of glucose- and glutamine-derived
carbons to fatty acids in SK-N-BE(2) cells with and without inhibition ofMYCN-expression. Figure 3A shows
a schematic depiction of glucose- or glutamine-derived labeled carbon distribution into citrate, an inter-
mediary of the tricarboxylic-acid cycle that acts also as a precursor for cytosolic production of Acetyl-
CoA for fatty acid synthesis, or into palmitate. As shown in Figures 3A and 3B, MYCN downregulation
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Figure 3. Inhibition of fatty acid synthesis has a broad impact on cellular lipid composition and affects mitochondrial morphology and function,
related to Figure S3
(A) Schematic representation labeled carbon distribution from glucose and glutamine in the metabolomics experiment shown in (B).
(B) Comparison of mass isotopologue distribution of palmitate was measured in SK-N-BE(2) cells treated with vehicle or the MYCN inhibitor 10058-F4 for
5 days. Glucose- and glutamine-derived carbons incorporated into palmitate were measured by metabolic tracing using U-13C6-glucose or U-
13C5-
glutamine as indicated.
(C) Abundance of the indicated fatty acid species in SK-N-BE(2)shMYCN cells treated with vehicle or doxycycline for 72 h, determined by LC.
(D) Abundance of the indicated fatty acids in SK-N-BE(2) cells treated for 7 days with vehicle or the indicated fatty acid synthesis inhibitors, determined by LC.
(E) Transmission electron microscopy images of representative mitochondria in SK-N-BE(2) cells treated for 7 days with vehicle or the indicated fatty acid
synthesis inhibitors. Scale bars indicate 1 mm.
(F) Transmission electronmicroscopy images of representative mitochondria in SH-EP cells treated for 7 days with vehicle or the indicated fatty acid synthesis
inhibitors. Scale bars indicate 1 mm.
(G) Quantification of oxygen consumption rate (OCR, left panel) and extracellular acidification rate (ECAR, right panel) in SK-N-BE(2) cells treated for 72 h
with vehicle or the indicated fatty acid synthesis inhibitors.
(H) Quantification of OCR (left panel) and ECAR (right panel) in SH-EP cells treated for 72 h with vehicle or the indicated fatty acid synthesis inhibitors.
All data are presented as meanG SD of at least three independent experiments; statistical analysis: t test with *, **, ***, and **** indicating p < 0.05, p < 0.01,




Articleincorporation of glutamine was reduced. Interestingly, there was a marked increase in the M+1 and M+3
isotopologues (NP+1 and NP+3) after MYCN inhibition in the glutamine-labeled samples. This isotopo-
logue pattern most likely indicates that the relative contribution of glutamine to fatty acid synthesis via
reductive carboxylation is increased when MYCN is inhibited, which results in odd-numbered acetyl-
CoA labeling. Conversely, in the absence of MYCN inhibition, glutamine is used to fuel anaplerosis.
Furthermore, odd-numbered palmitate isotopologues labeled from glucose were also increased after
MYCN inhibition, indicating a higher contribution of pyruvate anaplerosis via carboxylation. This suggests
that MYCN promotes glutamine- but inhibits pyruvate-dependent anaplerosis. In addition, we analyzed
fatty acid composition upon MYCN downregulation in SK-N-BE(2)shMYCN cells (Henriksen et al., 2011).
Palmitic, palmitoleic, stearic, and oleic acids were all reduced to around 50% of the initial amount after
72 h of MYCN downregulation. Importantly, the essential fatty acid linoleic acid was also diminished to a
similar extent, suggesting that not only reduced synthesis, but, in addition, decreased uptake of fatty acids
may occur as a consequence of lower MYCN expression (Figure 3C).
We were next interested in the changes in lipid composition in neuroblastoma cells following inhibition of
fatty acid synthesis. TOFA, Orlistat, Cerulenin, and UB006 led to a reduction in most of both the saturated
and unsaturated fatty acids quantified (Figures 3D and S3A). Some exceptions were the long chain fatty
acids docosanoic acid (C22:0), which was augmented by Cerulenin and UB006, and tetracosanoic acid
(C24:0), which was increased by all treatments used (Figure S3A). TOFA and Orlistat reduced ceramide
and cholesterol content (Figure S3B and S3C), whereas some sphingomyelins were unaffected and others
reduced or increased (Figure S3D). Because sphingomyelins are synthesized from ceramides, these effects
might reflect complex regulatory mechanisms of the sphingomyelin synthesis/degradation balance de-
pending on the availability of substrates. Treatment of SK-N-BE(2) cells with TOFA or Cerulenin led to
increased levels of free acetyl-CoA (Figure S3E), in agreement with reduced demand of this substrate
for the synthesis of fatty acids. Interestingly, increased levels of acetyl-CoA did not result in higher histone
acetylation; instead, inhibition of fatty acid synthesis reduced the levels of acetyl H3K9 and acetyl H3K27
already after 24 h of treatment (Figure S2F). This is in line with previous data showing that reduced histone
acetylation is a consequence of the differentiation of neural progenitors into neurons, oligodendrocytes,
and astrocytes (Hsieh et al., 2004).
The analysis of cellular ultrastructure upon fatty acid synthesis inhibition showed that TOFA, Cerulenin, and
Orlistat treatments resulted in profound changes in mitochondrial size, structure, and/or electron density
both in MNA (SK-N-BE(2)) and NMNA (SH-EP and SK-N-SH) neuroblastoma cells (Figures 3E, 3F, and S3G).
Because mitochondrial structure is linked to functionality, we studied oxidative phosphorylation (OXPHOS)
as well as glycolysis using the Seahorse extracellular flux analyzer after fatty acid synthesis inhibition. TOFA
strongly diminished mitochondrial respiration and all associated parameters in SK-N-BE(2), SH-EP, SK-N-
SH, KELLY, and IMR-32 cells and induced glycolysis in all the cell lines analyzed, except in IMR-32 cells (Fig-
ures 3G, 3H, and S3H–S3J). Cerulenin decreased ATP production in SK-N-BE(2) cells (Figure 3G), reduced
all OXPHOS-related parameters in SK-N-SH (Figure S3H), but had no effect on OXPHOS either in SH-EP
(Figure 3H) or KELLY cells (Figure S3I). Conversely, it induced glycolysis in both cell lines (Figures 3H and
S3I). Treatment of SK-N-BE(2) cells with UB006 did not affect OXPHOS but slightly decreased the glycolytic8 iScience 24, 102128, February 19, 2021




Figure 4. Induction of differentiation upon fatty acid synthesis inhibition is dependent on ERK signaling, related to Figure S4
(A) Fold change in phosphorylation of the indicated proteins in SK-N-BE(2) cells treated for 24 h with TOFA or Cerulenin versus vehicle, as measured by a
phospho-antibody microarray.
(B) Western blot analysis of the indicated proteins, in their total or phosphorylated forms, in SK-N-BE(2) cells treated for 24 h with DMSO (D), TOFA (T), or
Cerulenin (C).
(C) Western blot analysis of the indicated proteins, in their total or phosphorylated forms, in SK-N-BE(2) cells treated for 72 h, as indicated.
(D) Western blot analysis of the indicated proteins, in their total or phosphorylated forms, in SK-N-BE(2) cells treated for 7 days, as indicated.
(E) Western blot analysis at the indicated time points of total ERK or phospho-ERK in SK-N-BE(2) cells treated as indicated.
(F) Immunofluorescence staining of SK-N-BE(2) cells treated for 7 days with vehicle, TOFA, or Cerulenin G SCH772984. Blue: DAPI; green: Tubulin B3. Scale
bar indicates 20 mm.
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(G) Western blot analysis of total and phosphorylated ERK and MYCN in SK-N-BE(2) cells treated for 72 h with DMSO (D), TOFA (T), Cerulenin (C) G
SCH772984 (S).
(H) mRNA fold expression of SCG2 and NPY in SK-N-BE(2) treated for 7 days with vehicle or the indicated treatments, as quantified by qPCR. Western blot
and microscopic images are representative of at least three independent experiments. Ponceau staining was used as a loading control in the Western blots.
qPCR data are presented as meanG SD of at least three independent experiments; statistical analysis: t test with *, **, and *** indicating p < 0.05, p < 0.01,




Articlecapacity and reserve (Figure 3G). In IMR-32 cells, UB006 resulted in a reduction of all OXPHOS-related pa-
rameters as well as a small reduction in glycolysis (Figure S3J). Notably, the mitochondrial changes result-
ing after fatty acid inhibition do not seem to be a general feature upon differentiation, as they were not
observed in SK-N-BE(2) differentiated with ATRA (Figure S3K). Furthermore, UB006 treatment led both
to increased OXPHOS as well as to higher glycolysis in SK-N-BE(2) cells (Figure S3L). In summary, inhibition
of fatty acid synthesis resulted in lower OXPHOS functionality with a slight increase in glycolysis, probably
as a response to compensate for the reduced mitochondrial energy production, and these effects are not
mimicked by ATRA, a well-known differentiation agent in neuroblastoma.Induction of differentiation upon fatty acid synthesis inhibition is dependent on ERK signaling
To shed light into the signaling pathways activated by inhibition of fatty acid synthesis in neuroblastoma
cells, we analyzed extracts of SK-N-BE(2) cells treated for 24 h with either TOFA or Cerulenin using a phos-
pho-antibody array. ERK1/2, CREB, AMPKa, and AKT were among the most upregulated phosphorylated
proteins (Figure 4A). Validation by Western blot of some of the proteins in the array using antibodies
against the phosphorylated and total forms confirmed that phosphorylation was indeed increased 24 h af-
ter fatty acid synthesis inhibition (Figure 4B). At 72 h of treatment the levels of p-AKT, p-AMPKa, and p-
CREB were still elevated, whereas at 7 days of inhibition, phosphorylation levels, except p-AMPKa after
Cerulenin, and p-AKT after either of the two inhibitors, had descended (Figures 4C and 4D). In addition,
ERK1/2 also showed increased phosphorylation at time points ranging from 24 h to 7 days in IMR-32
and SK-N-AS cells (Figures S4A–S4C). Similarly, phospho-AMPKa was increased in SH-SY5Y at both 72 h
and 7 days after treatment (Figure S4D and S4E). In contrast, phosphorylation of CREB was not observed
in either IMR-32 or SH-SY5Y cells (Figures S4B, S4D, and S4E).
Because of the known involvement of ERK1/2 in cell survival and differentiation (O’Neill and Kolch, 2004)
and since it was one of the most strongly phosphorylated proteins in the array as well as consistently phos-
phorylated in different MNA and NMNA neuroblastoma cell lines treated with fatty acid synthesis inhibi-
tors, we analyzed their phosphorylation and thus activation in more detail. Time course experiments
showed that neither TOFA nor Cerulenin induced any changes in ERK1/2 phosphorylation at early time
points (5, 15, and 30 min) but increased phosphorylation at around 5 hours after inhibition. The phosphor-
ylation remained elevated in comparison with vehicle-treated cells up to 7 days of treatment (Figure 4E).
These results indicate that the effect on the activation of ERK1/2 is not an immediate consequence of
the addition of the inhibitors to the cells, instead it requires hours to occur, probably reflecting that this
activation is triggered by the metabolic effects of the fatty acid inhibitors and not by some side effects.
To determine the potential involvement of the AKT signaling pathway in the induction of differentiation by
inhibition of fatty acid synthesis, we treated SK-N-BE(2) with the AKT1/2 kinase inhibitor VIII trifluoroace-
tate. We observed that AKT inhibition alone, as expected, led to reduced MYCN protein levels (Ruiz-Pérez
et al., 2015) and that it was unable to prevent the MYCN downregulation induced by TOFA (Figure S4F).
Furthermore, AKT inhibition did not prevent the induction of neural differentiation by TOFA, evaluated
both by SCG2 expression and by neurite outgrowth, whereas VIII trifluoroacetate did not have any impact
on differentiation as a single agent (Figures S4F and S4G).
We next evaluated the involvement of ERK1/2 activation in the induction of differentiation. For this pur-
pose, we treated SK-N-BE(2) cells with vehicle, TOFA, or Cerulenin alone or in combination with the
ERK1/2 inhibitor SCH772984. We found that ERK1/2 inhibition prevented neural differentiation induced
by fatty acid synthesis block, indicating the participation of the ERK signaling pathway in this process (Fig-
ure 4F). SCH772984 completely prevented ERK1/2 activation upon TOFA and Cerulenin treatment and
rescued MYCN protein levels when combined with the fatty acid synthesis inhibitors, even though it led




Figure 5. Inhibition of fatty acid synthesis reduces neuroblastoma tumor growth and increases differentiation in vivo, related to Figure S5
(A) Tumor index (volume each day/initial volume) of a xenograft model with IMR-32 cells. NMRI nude mice were treated daily with vehicle (10%
b-cyclodextrin), 30 mg/kg TOFA, 100 mg/kg Orlistat, or 20 mg/kg UB006. n = 4 per group.
(B) Tumor weight at the experiment endpoint for the tumors presented in (A).
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(C) Representative pictures of the IMR-32 xenograft tumors at the experimental endpoint.
(D) Microscopic images of IHC staining of IMR-32 xenograft tumors labeled with anti-Ki67, anti-MYCN, anti-Tubulin B3, and anti-SCG2 anti bodies. Scale bars
indicate 50 mm.
Data are presented as mean G SD. Statistical analysis: t test with *, **, ***, and **** indicating p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.




ArticleSCH772984 blocked the increase in mRNA levels of the differentiation markers SCG2 and NPY, which are
upregulated by TOFA or Cerulenin alone (Figure 4H).
Our results therefore suggest that activation of ERK signaling plays an important role in the induction of
differentiation in neuroblastoma cells upon inhibition of fatty acid synthesis.Inhibition of fatty acid synthesis reduces neuroblastoma tumor growth and increases
differentiation in vivo
As presented earlier, inhibition of fatty acid synthesis in neuroblastoma cells in vitro led to reduced cell
growth, increased cell death, downregulation of MYC(N), and neural differentiation. To evaluate the poten-
tial of inhibiting fatty acid synthesis in vivo we performed xenograft experiments in nude mice. To this end,
we injected twoMNA cell lines (IMR-32 and SK-N-BE(2)) and one NMNA cell line (SK-N-AS) in the right flank
of nude mice. These neuroblastoma cell lines show high aggressiveness in vivo, giving rise to tumors that
reach the maximum ethically permitted volume of 1 cm3 in around 6 to 8 days, thus only allowing a very
short therapeutic window. IMR-32 xenografts were treated with either vehicle or 30 mg/kg TOFA (targeting
ACACA), 100 mg/kg Orlistat, or 20 mg/kg UB006 (both targeting FASN). All three inhibitors reduced tumor
growth as shown both by tumor volume index throughout the experiment, as well as by tumor weights at
endpoint (Figures 5A–5C). After resection, paraffin sections of the tumors were stained for markers of pro-
liferation and differentiation. We found that all treatments reduced the levels of Ki67 and MYCN, while
increasing the levels of the neural differentiation markers Tubulin B3 and SCG2 (Figure 5D).
Because UB006 gave the most robust reduction on tumor growth even though it was used at lower concen-
trations than the other two inhibitors, we used this compound to extend the analysis to one additional MNA
as well as one NMNA xenograft model. To this end we treated mice carrying tumors generated from SK-N-
BE(2) and SK-N-AS cells with either vehicle or 20 mg/kg UB006. Both xenograft models showed reduced
tumor volume and weight upon treatment with UB006 (Figures S5A–S5C and S5E–S5G) although not as
pronounced as on the IMR-32 tumors (Figures 5A–5C). The SK-N-BE(2) tumors showed a decrease in the
levels of both Ki67 and MYCN and increased expression of the differentiation markers Tubulin B3 and
SCG2 (Figure S5D). Similarly, Ki67 and c-MYC were reduced in SK-N-AS tumors; however, there was no
obvious increase in either Tubulin B3 or SCG2 levels (Figure S5H), in accordance with the lack of differen-
tiation of this cell line in vitro upon inhibition of fatty acid synthesis (Figure S1G).
Importantly, none of the treatments generated any observable health problems nor did they affect the total
body mass of any of the mice during the course of the experiment (Figure S5I), as an indication of low sys-
temic toxicity.
Our results highlight the potential of fatty acid synthesis inhibition as a therapeutic approach for neuroblas-
toma irrespective of MYCN-status.Expression of FASN and ACACA correlate with poor prognosis in neuroblastoma
To analyze the clinical relevance, we next analyzed the impact of mRNA expression levels of genes involved
in fatty acid synthesis for disease outcome. To this end, we evaluated the overall survival of neuroblastoma
patients in three independent datasets, referred to as Kocak (Kocak et al., 2013), Versteeg (Molenaar et al.,
2012), andNRC (Neuroblastoma Research Consortium) (Rajbhandari et al., 2018). The clinical parameters of
the patients in these datasets, in terms of INSS stage and MYCN-amplification, show similar proportions
(Figure 6A and Figure S6A). High expression of both FASN and ACACA correlated to reduced overall sur-
vival in all three cohorts (Figures 6B–6C). Because both genes have been described as c-MYC targets (Gouw
et al., 2019) and FASN also has been suggested to be a target of MYCN (Hsu et al., 2016), we analyzed the
correlation of both ACACA and FASN with survival in the non-MYCN-amplified patients. This analysis
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Figure 6. Expression of FASN and ACACA negatively correlates with good prognosis in neuroblastoma, related
to Figure S6
(A) Distribution of patients in the different INSS stages in the three neuroblastoma datasets (Kocak, Versteeg, and NRC)
analyzed in this study.
(B) Kaplan-Meier overall survival (OS) curves for each dataset based on the mRNA expression of the ACACA gene.
(C) Kaplan-Meier OS curves for each dataset based on the mRNA expression of the FASN gene.
(D–G) Boxplots of FASN expression related to (D) stage, (E) age, (F) quartiles of SCG2 expression, and (G) quartiles of
TRKA expression.
Statistics on boxplots for MYCN status and age: unpaired t test; statistics on boxplots for TRKA, SCG2, and stage: one-
way ANOVA. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively. p values of Mantel-Cox




Articledatasets except for ACACA in the Versteeg cohort (Figures S6B and S6C). In addition, the levels of both
genes were higher in MNA than in NMNA patients in the Kocak dataset (Figures S6D and S6E), whereas
only FASN expression was elevated in MNA versus NMNA patients in the two other cohorts (Figures
S6D and S6E).
We next analyzed the expression of ACACA and FASN in relation to clinical parameters with prognostic
value: disease stage, age at diagnosis (worse when older than 18 months), and expression levels of
TRKA and SCG2,markers of both neural differentiation and good prognosis. FASNwas expressed at higher
levels in stages 3 and 4 and reduced in stage 4S patients in all three cohorts (Figure 6D), whereas ACACA
expression showed no significant relation to disease stage in any of the datasets (Figure S6F). Patients older
than 18 months at the time of diagnosis showed significantly higher levels of expression of FASN in all co-
horts (Figure 6E), whereas significant differences between age groups were only observed in the Versteeg
dataset for ACACA (Figure S6G). Notably, high FASN expression was found in patients with low SCG2 or
TRKA levels in all cohorts (Figures 6F and 6G), whereas elevated ACACA levels were only observed in tu-
mors with low TRKA in the Kocak dataset (Figure S6H).
Collectively, these data suggest that although high expression of both ACACA and FASN consistently cor-
relates to reduced survival in tumors independently of theirMYCN status, FASN seems to be a better prog-
nosis marker candidate for neuroblastoma patients.DISCUSSION
In spite of the development of more efficient therapies, high-risk neuroblastoma remains a highly deadly
disease, with a survival rate of just 50%, and the harsh treatment regimens may result in reduced quality of
life (Perwein et al., 2011). It is thus urgent to develop new therapeutic approaches. AlthoughMYCN-ampli-
fication strongly correlates to poor clinical outcome in neuroblastoma patients, there are no MYC-targeted
therapies available in the clinic to date. Targeting processes downstream of theMYC protein, such as meta-
bolism, andmost relevant for this study, lipogenesis, has been suggested as a potent strategy to overcome
difficulties of directly targeting MYC (Dang et al., 2017; Gouw et al., 2019).
Tumor cells undergo changes in metabolism to sustain cell growth and division (Cantor and Sabatini, 2012).
Lipids are important not only as energy sources and structural components of membranes but also as
signaling molecules (Snaebjornsson et al., 2020). The activation of de novo fatty acid synthesis occurs in
multiple cancers (Rohrig and Schulze, 2016), and its inhibition has shown promising antitumor activity in
a number of tumor types, such as ovarian (Pizer et al., 1996b; Zhou et al., 2007), breast (Pizer et al.,
1996a; Thupari et al., 2001; Vazquez-Martin et al., 2007; Menendez and Lupu, 2017), prostate (Pflug
et al., 2003; Pizer et al., 2001), lung (Orita et al., 2007), colon (Murata et al., 2010), and others (Menendez
and Lupu, 2007; Gouw et al., 2019). However, except for one study showing reduced viability of SK-N-SH
cells upon treatment with Cerulenin (Slade et al., 2003), the relevance of de novo fatty acid synthesis for
neuroblastoma has not been previously evaluated.
Using five small molecule inhibitors targeting ACACA or FASN and siRNA targeting FASN, we show that
inhibition of fatty acid synthesis decreases cell proliferation, reduces MYCN or c-MYC protein levels,
and results in neural differentiation in neuroblastoma. We have analyzed these effects in ten neuroblas-
toma cell lines, two neuroblastoma PDX-derived cell cultures, one ex vivo model system, and three xeno-




Articleanalyzing gene expression data from primary neuroblastoma tumors from three independent patient
datasets.
In contrast to inhibition of fatty acid b-oxidation, which is a vulnerability mainly in MNA neuroblastoma
(Oliynyk et al., 2019), fatty acid synthesis can be successfully targeted in both MNA and NMNA neuroblas-
toma cell lines. We demonstrate that the consequences of fatty acid synthesis inhibition are specific for
reduced lipid availability, as they can be rescued by exogenous oleate and because none of these effects
are observed upon glucose or glutamine starvation.
Inhibition of fatty acid synthesis in vivo, both targeting ACACA with TOFA or FASN with either Orlistat or
UB006, not only reduced tumor growth, but importantly led to neural differentiation, as assessed by
expression of differentiation markers. These effects were striking especially when taking into account
that these neuroblastoma xenograft models are very aggressive and only allow for a very short therapeutic
window of 6 to 8 days after treatment initiation.
We found that MYCN levels and activity have a direct effect on fatty acid amount, as well as on glucose as
the preferred carbon source for fatty acid synthesis in neuroblastoma, in agreement with our earlier results
(Oliynyk et al., 2019) and studies in other MYC-driven tumors (Eberlin et al., 2014; Edmunds et al., 2014;
Morrish et al., 2010; Gouw et al., 2019). We previously showed that MYCN downregulation leads to
enlarged mitochondria with fewer cristae and reduced OXPHOS capacity (Oliynyk et al., 2019). Here we
demonstrate that inhibition of fatty acid synthesis leads to a similar phenotype, most likely due to dimin-
ished MYC(N) levels. We also observed changes in cholesterol and ceramide levels. Although ceramides
are fatty acid derivatives, and thus, reduced fatty acid content has a direct impact on their synthesis, choles-
terol is produced in an independent pathway. However, cholesterol homeostasis is very dynamic, and
changes in other lipids can affect cholesterol uptake, stabilization, and content (Mesmin and Maxfield,
2009). Interestingly, increased levels of p-AMPKa observed upon fatty acid synthesis inhibition may reflect
a reduction of the energy production in the cells. Active p-AMPKa is known to inhibit biosynthetic pro-
cesses, including cholesterol synthesis (Srivastava et al., 2012). These extended signaling processes may
explain the effects of fatty acid synthesis inhibitors on cholesterol levels.
Our results suggest that the induction of differentiation is mediated by activation of ERK signaling, as this
protein was phosphorylated in neuroblastoma cells subjected to fatty acid synthesis block, whereas cells
were unable to differentiate when ERK activation was prevented. Although in the context of cancer biology,
active ERK is usually associated to increased survival, proliferation, and malignancy (Samatar and Poulika-
kos, 2014), the RAF-MEK-ERK signaling pathway is also associated with neural differentiation under the
control of the receptor for nerve growth factor (NGF), the neurotrophic tyrosine kinase receptor A
(TRKA) (Khotskaya et al., 2017). Notably, inhibition of AKT, which lies downstream of the neurotrophin-3
receptor, TRKC (Khotskaya et al., 2017), did not affect the induction of differentiation mediated by fatty
acid synthesis inhibition. Remarkably, agents that trigger differentiation of neuroblastoma or pheochromo-
cytoma require the activation of several signaling pathways including ERK (Zogovic et al., 2015; Liu et al.,
2015). ERK proteins can in turn phosphorylate more than six hundred different targets, including transcrip-
tion factors, in a context-dependent manner (Unal et al., 2017), which explains their wide range of effects.
Importantly, our in silico analysis showed that high FASN expression was found in patients with low TRKA
levels in all three cohorts. Together, these data suggest that the TRKA-signaling pathway through ERK1/2 is
activated by inhibition of fatty acid synthesis.
Importantly, we observed downregulation of MYCN/c-MYC protein levels upon inhibition of fatty acid syn-
thesis. Among the pleiotropic functions of MYC, there is a well-stablished role in promoting proliferation
and opposing differentiation both in normal physiological and cancer contexts (Dang, 2012; Yoshida,
2018). It has been reported that neuroblastoma cell differentiation requires a timely regulation of MYCN
expression, with early overexpression (Guglielmi et al., 2014), followed by downregulation (Huang and
Weiss, 2013). The downregulation of MYC proteins by inhibition of fatty acid synthesis could in this way
be involved in the observed induction of neural differentiation.
Neuroblastoma is thought to originate from cells of embryonic origin blocked in an undifferentiated
phenotype (Brodeur, 2003). Among all human cancers, it has the highest rate of spontaneous maturation




Articleinduce the neuroblastomas that do not spontaneously differentiate into a differentiation process by ther-
apeutic intervention. This hypothesis has led to a search for agents able to promote neuroblastoma cell
maturation. Retinoids are used for the maintenance phase of treatment, but their overall benefits are un-
clear (Peinemann et al., 2016; Matthay et al., 2009). Finding novel agents able to induce differentiation is an
important goal in the development of new treatments for neuroblastoma.
Inhibitors of both ACACA and FASN have been available for some time (Buckley et al., 2017; Wang et al.,
2015); however, very few have made their way into clinical trials, despite promising effects in preclinical
studies (Rohrig and Schulze, 2016). Importantly, of the inhibitors used here, only Orlistat is FDA approved
and not for cancer but for the treatment of obesity (Ameer and Weintraub, 2018). All inhibitors in this study
(Figure 1A), except UB006, have been employed by others to target fatty acid synthesis in vitro and in vivo in
different tumor types. UB006 is a C75-derived FASN inhibitor devoid of the anorexigenic side effects asso-
ciated to the parent compound (Makowski et al., 2017). It has previously not been used for treatment of
tumor-carrying mice. Here we demonstrate that UB006 efficiently decreases neuroblastoma tumor growth,
showing a more potent effect than TOFA and Orlistat, without affecting animal weight. Based on these
promising results, we suggest that further studies on UB006 toxicology and bioavailability are justified.
Our analysis showed that high levels of bothACACA and FASN correlate with reduced survival in three neu-
roblastoma patient cohorts covering all five INSS stages and with similar proportion of MYCN-amplifica-
tion. Notably high FASN expression is related to low levels of neural differentiation markers and to poor
prognosis factors, suggesting that it may have a prognostic value in neuroblastoma.
Our results demonstrate that inhibition of fatty acid synthesis induces differentiation in neuroblastoma
independently ofMYCN-status, providing approaches for development of more specific fatty acid synthe-
sis inhibitors that can be used in the clinic.
Limitations of the study
Our xenograft models are performed in immunocompromised mice. Future studies should analyze the in-
fluence of the environment, including the immune compartment, on the effects of fatty acid synthesis inhi-
bition in neuroblastoma tumors. In addition, the cell lines used to perform the xenograft experiments show
a very fast and aggressive growth to form tumors, limiting the therapeutic window to a range of 6 to 8 days.
Both limitations could be overcome by using the transgenic TH-MYCN neuroblastoma mouse model,
which possesses an intact immune system and spontaneously develops neuroblastoma tumors that highly
resemble the characteristics of human neuroblastoma.
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Figure	 S2.	 Related	 to	 Figure	 2.	 Induction	 of	 differentiation	 is	 not	 a	 general	 response	 to	
nutrient	starvation,	but	a	specific	consequence	of	diminished	fatty	acid	synthesis	and	lipid	
withdrawal		
A)	 Enzymatic	 reactions	 inhibited	 by	 CI-976.	 LPAT:	 lysophospholipid	 acyltransferase;	 ACAT:	
sterol	O-acyltransferase.	B)	Western	blot	analysis	of	MYCN	protein	in	SK-N-BE(2)	cells	treated	
with	vehicle,	TOFA,	or	Cerulenin	±	BSA/BSA-bound	oleate	for	three	or	seven	days.	b-actin	was	

































































































































































































































































































































































































































































































































































cells	 treated	 for	 seven	days	with	vehicle	or	 the	 indicated	 fatty	acid	 synthesis	 inhibitors.	F)	
Western	blot	analysis	of	acetyl	H3K9,	Acetyl	H3K27	and	total	histone	3	(H3)	in	SK-N-BE(2)	cells	
treated	with	vehicle,	TOFA,	or	Cerulenin	for	24	hours.	Ponceau	staining	was	used	as	loading	







synthesis	 inhibitors.	 K)	 Transmission	 electron	 microscopy	 images	 of	 representative	
mitochondria	 in	 SK-N-BE(2)	 cells	 treated	 for	 seven	 days	 with	 vehicle	 or	 ATRA.	 Scale	 bars	
indicate	1	µm.	L)	Quantification	of	OCR	(left	panel)	and	ECAR	(right	panel)	in	SK-N-BE(2)	cells	
treated	for	72	h	with	vehicle	or	ATRA.	
All	data,	except	where	 indicated,	 is	presented	as	mean	±	SD	of	at	 least	three	 independent	
experiments;	statistical	analysis	t-test	with	*,	**,	***,	****	indicating	p<0.05,	p<0.01,	p<0.001	
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Figure	 S4.	 Related	 to	 Figure	 4.	 Induction	 of	 differentiation	 upon	 fatty	 acid	 synthesis	
inhibition	is	dependent	on	ERK	signaling		
A-C)	Western	blot	analysis	of	the	indicated	proteins,	in	their	total	forms	or	phosphorylated	in	
the	 indicated	 residues,	 in	 IMR-32	 cells	 treated	 for	 24	 h	 (A),	 72	 h	 (B)	 or	 seven	 days	 (C)	 as	











































































































































































endpoint.	Data	 is	 presented	 as	mean	 ±	 SD.	 Statistical	 analysis:	 t	 test	with	 *,	 **	 indicating	
p<0.01	and	p<0.001,	respectively.	H)	Microscopic	images	of	IHC	staining	of	SK-N-AS	xenograft	
tumors	labeled	with	anti-Ki67,	anti-c-MYC,	anti-Tubulin	B3,	and	anti-SCG2	antibodies.	Scales	




























































































































































































































































































































































A)	 Distribution	 of	 patients	 into	MYCN-amplified	 or	 non-amplified	 categories	 in	 the	 three	
neuroblastoma	datasets	(Kocak,	Versteeg,	and	NRC)	analyzed	in	this	study.	B)	Kaplan-Meier	
overall	 survival	 (OS)	 curve	 of	 the	 non-MYCN-amplified	 (NMNA)	 patients	 from	 the	 three	
cohorts	based	on	the	mRNA	expression	of	ACACA.	C)	Kaplan-Meier	overall	survival	(OS)	curve	
of	 the	 non-MYCN-amplified	 (NMNA)	 patients	 from	 the	 three	 cohorts	 based	 on	 the	mRNA	
expression	of	FASN.	D)	Boxplots	of	FASN	expression	related	to	MYCN-amplification	status.	E)	
























































(50-60%)	 were	 controlled.	 Food	 and	 water	 were	 available	 ad	 libitum.	 For	 xenograft	
experiments,	10	x	106	SK-N-BE(2),	IMR-32,	or	SK-N-AS	cells	were	injected	subcutaneously	into	
the	right	flanks.	IMR-32	cells	were	injected	in	a	1/3	Matrigel	(Sigma-Aldrich)	dilution.	The	other	
cell	 lines	 were	 prepared	 in	 culture	 medium	 without	 supplements.	 Tumor	 growth	 was	
monitored	daily	by	caliper	measurement	of	three	dimensions.	Tumor	take	point	was	defined	
as	a	tumor	volume	equal	to	0.1	cm3.	The	animals	were	then	randomized	into	the	treatment	
groups	 and	 received	 daily	 i.p.	 injections	 with	 either	 vehicle	 (10	 %	 2-(hydroxypropyl)-β-
cyclodextrin	in	H2O)	or	30	mg/kg	TOFA,	100	mg/kg	Orlistat,	or	20	mg/kg	UB006.	The	mice	were	


















expressing	 a	 doxycycline	 inducible	 MYCN-shRNA,	 and	 the	 Tet-21/N	 cells,	 expressing	 a	
doxycycline-repressible	MYCN	gene,	were	cultured	in	the	same	medium	supplemented	with	
10	%	tetracycline-approved	FBS	(Clontech).		Human	neuroblastoma	IMR-32	cells	were	grown	
in	 low	 glucose	 DMEM	 (Sigma-Aldrich)	 supplemented	 as	 described	 above.	 Human	 primary	
fibroblasts	were	grown	in	DMEM	(Gibco)	supplemented	with	10	%	FBS,	1	%	glutamine	and	1	
%	penicillin-streptomycin.	The	PDX-derived	cell	cultures	LU-NB-2	and	LU-NB-3	were	cultured	
as	 previously	 described	 (Persson	 et	 al.,	 2017).	 Briefly,	 the	 cells	 were	maintained	 in	 a	 3:1	
mixture	 of	 DMEM:F12	 supplemented	 with	 40	 ng/ml	 FGF,	 20	 ng/ml	 EGF,	 1%	 penicillin-
streptomycin	 and	 2%	B27	without	 vitamin	A.	 For	 differentiation	 experiments,	 plates	were	
coated	with	Biolaminin	521	LN	(Biolamina).		
The	 sex	 and	 other	 information	 of	 the	 patients	 from	 which	 the	 different	 cell	 lines	 were	
generated	is	provided	in	Supplemental	Table	1.		
Small	molecules,	inhibitors	and	treatments	













SK-N-BE(2)	 were	 plated	 in	 6	 well	 plates	 at	 a	 density	 of	 50	 000	 cells/well	 and	 incubated	
overnight.		The	next	day,	the	cells	were	transfected	with	30	nM	siRNA	targeting	human	FASN	
(s5032,	 ThemoFisher	 Scientific)	 or	 with	 a	 negative	 control	 siRNA	 (4390846,	 ThemoFisher	














supplemented	 with	 5	 mM	 sodium	 butyrate	 to	 retain	 histone	 acetylation.	 Cells	 were	 re-
suspended	and	lysed	for	10	min	on	ice	with	gentle	stirring,	using	Triton	Extraction	Buffer	(TEB)	












For	probing	 FASN,	 3-8%	Tris-acetate	 gels	 (Thermo	Fisher	 Scientific)	 and	wet	 transfer	 for	 3	
hours,	 70	 V	were	 used.	 For	 analyzing	 histones,	 18%	 polyacrylamide	 gels	were	 used.	 After	
blocking	 with	 non-fat	 milk,	 the	 membranes	 were	 incubated	 with	 the	 corresponding	
antibodies.	The	monoclonal	antibodies	for	c-Myc	(9E10),	MYCN	(B8.4.B),	β-Actin	(C4),	and	α-
Tubulin	(DM1A)	were	from	Santa	Cruz	Biotechnology.	The	monoclonal	antibodies	for	AMPKa,	
phospho-AMPKa	 (40H9),	 ERK,	 phospho-ERK,	 AKT,	 phospho-AKT	 (D9E),	 GSK3b	 (27C10),	
phospho-GSK3b,		CREB	(D76D11),	phospho-CREB	(1B6),	acetyl-histone	H3	Lys	9	(C5B11)	and	










0.05	%	 sodium	azide,	 all	 from	Sigma-Aldrich,	 in	PBS).	 Primary	antibodies	 (Tubulin	B3	 from	
Abcam;	TrkA	from	Millipore,	vimentin	(V9)	from	DAKO;	SCG2	from	Atlas	antibodies)	diluted	in	
blocking	solution	were	incubated	overnight	at	+4°C.	After	washing,	the	slides	were	incubated	
for	 1	 h	 at	 room	 temperature	 with	 the	 appropriate	 fluorophore-conjugated	 antibodies	
(AlexaFluor	568	and	488,	Thermo	Fisher	Scientific).	DAPI	 (1:10,000;	 Life	Technologies)	was	
used	 for	nuclear	 stain.	Pictures	were	 taken	on	a	Zeiss	Axiovert	200M	microscope	with	 the	
Axiovision	 software,	 or	 in	 an	 Olympus	 IX73	 microscope	 with	 the	 CellSens	 Dimensions	
software.	The	pictures	showed	here	are	representative	of	three	independent	experiments.	
Immunohistochemistry	analysis	of	tumor	sections	
For	 immunohistochemistry	 (IHC)	 on	 IMR-32,	 SK-N-BE(2),	 and	 SK-N-AS	 xenograft	 tumors,	
transverse	sections	of	5	μm	thickness	from	paraffin-embedded	tissues	were	stained	with	the	
EnVision	 System	 (Dako)	 according	 to	 the	manufacturer’s	 instructions.	 Briefly,	 paraffin	was	
removed	and	samples	were	re-hydrated	by	consecutive	xylol-alcohol	(all	from	Sigma-Aldrich)	
gradients.	Sample	blocking	was	followed	by	overnight	incubation	at	+4°C	with	the	following	
primary	 antibodies	 diluted	 in	 blocking	 solution:	 rabbit	 anti-Ki67	 (1:250,	 Abcam	 ab16667),	
mouse	anti-MYCN	(1:200,	Santa	Cruz	sc-56729),	rabbit	anti	c-MYC	(1:250,	Santa	Cruz	sc-789),	
mouse	 anti-tubulin	 B3	 (1:250,	 Abcam	 ab7751)	 or	 rabbit	 anti-SCG2	 (1:250,	 Sigma-Aldrich	
HPA011893).	Samples	were	incubated	with	HRP-polymer	for	20	min,	followed	by	30	seconds-
3	 min	 incubation	 with	 DAB	 working	 solution.	 Nuclear	 staining	 with	 Meyer’s	 hematoxylin	
(Dako)	 was	 performed	 for	 2	 min.	 Samples	 were	 dehydrated	 by	 consecutive	 alcohol-xylol	
gradients	 and	mounted	with	Roti-histokitt	mounting	medium	 (Roth).	 The	pictures	 showed	
here	are	representative	of	three	independent	experiments.	
Phospho-antibody	array	























Total	 RNA	was	 isolated	 using	 TRIzol	 reagent	 (Invitrogen)	 and	 cleaned	 up	 with	 RNeasy	 kit	
(Qiagen).	 cDNA	 was	 synthesized	 using	 iScript	 cDNA	 synthesis	 kit	 (Bio-Rad)	 according	 to	
manufacturer’s	 instructions.	Real-time	qPCR	analyses	of	mRNA	expression	 for	MYCN	using	
iTaq	universal	SYBR	Green	supermix	(BioRad)	was	carried	out	on	a	StepOnePlus	Real-Time	PCR	
system	(Applied	Biosystems)	according	 to	manufacturer’s	 instruction.	Samples	were	 run	 in	





































Free	 fatty	acids	and	 internal	standard	mixture	 (heptadecanoic	acid,	deuterated	palmitoleic	
acid	and	deuterated	docosahexaenoic	acid)	were	extracted	with	0.5	ml	of	the	organic	solvent	
mixture,	 isopropanol:	 n-heptane:	 1	 M	 hydrochloric	 acid	 (40:10:1	 v/v/v)	 for	 15	 minutes.	
Samples	were	kept	at	 room	temperature	 for	10	min	 followed	by	 the	addition	of	0.5	ml	of	
water.	Plasma	lipids	were	extracted	into	1	ml	of	n-heptane.	During	the	extraction,	the	lipids	
were	protected	against	oxidation	by	 the	addition	of	0.05	mg/ml	butylated	hydroxytoluene	





























































acetonitrile/isopropanol	 (4:3,	 v/v).	 The	 separation	 was	 achieved	 at	 room	 temperature	




3200	Q	trap	mass	spectrometer	 (Applied	Biosystems).	At	 the	end	of	each	 injection,	a	start	
signal	 was	 sent	 to	 the	 MS	 to	 start	 data	 acquisition.	 The	 MS	 was	 run	 multiple	 reactions	
monitoring	(MRM)	mode	with	the	transitions	obtained	from	(Bielawski	et	al.,	2006).	Duplicate	
analyses	 of	 each	 sample	were	 performed	 and	 the	 average	 values	were	 reported	 for	 both	
ceramides	and	sphingomyelin	(CV	<	11	%).	The	linearity	of	the	method	was	evaluated	over	a	
range	of	concentrations	 for	ceramides	and	sphingomyelin	of	0.1	 -	100	µM	and	0.1-30	µM,	






glutamine	 (both	 from	 Cambridge	 Isotopes	 Laboratories).	 The	 cells	 were	 then	 cultured	 for	





dryness	 under	 N2	 at	 +45°C.	 For	 saponification	 lipids	 were	 resuspended	 in	 Methanol/H2O	
(80/20,	v/v)	containing	0.3	M	KOH,	heated	at	+80°C	for	1	h	and	washed	twice	with	0.5	mL	
hexane.	After	addition	of	50	µL	formic	acid,	fatty	acids	were	subsequently	extracted	twice	with	












equipment	 used	 for	 LC/MS	 analysis	 was	 a	 Thermo	 Fisher	 Scientific	 Dionex	 Ultimate	 3000	
UHPLC	system	hyphenated	with	a	Q	Exactive	mass	spectrometer	 (QE-MS)	equipped	with	a	
HESI	probe	(Thermo	Fisher	Scientific).	UPLC-precolumn:	Acclaim	C8	column	(5	μm	particles,	















defined	 by	 the	median,	 while	 SCG2	 and	 TRKA	 levels	 were	 presented	 as	 quartiles	 of	 gene	
expression	levels,	where	Low	=	Q1,	Medium	=	Q2,	Medium-High	=	Q3,	and	High	=	Q4.	When	
only	two	conditions	were	compared,	the	data	was	analyzed	by	Student’s	t-test.	Significance	







KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 




















α-Tubulin (DM1A) Santa Cruz 
Biotechnology 
Cat# sc-32293  








































Acetyl-Histone H3 Lys9 (C5B11)	 Cell Signaling 
Technology 
Cat# 9649  
RRID: AB_823528 




Tubulin B3 Abcam Cat# ab7751 
RRID: AB_306045 
Ki67 Abcam Cat# ab16667 
RRID: AB_302459 
Histone H3 Abcam Cat# ab1791 
RRID: AB_302613 
TRKA Millipore Cat# 06-574 
RRID: AB_310180 






FASN Novus Cat# NB400-114 
RRID: AB_10002181 
Proteome Profiler Human Phospho-Kinase Array Kit  R&D Systems Cat# ARY003C 
Chemicals, Peptides, and Recombinant Proteins 
Seahorse XF glycolysis stress test kit Agilent Cat# 103020-100 
Seahorse XF Mitostress kit Agilent Cat# 103015-100 
Seahorse XF Base medium Agilent Cat# 103334-100 
Seahorse FluxPak Agilent Cat# 102416-100 








ATRA Sigma-Aldrich Cat# R2625 
TOFA Sigma-Aldrich Cat# T6575 
CAS 54857-86-2 
Cerulenin Sigma-Aldrich Cat# C2389 
Orlistat Sigma-Aldrich Cat# O4139 
10058-F4 Sigma-Aldrich Cat# F3680 
VIII trifluoroacetate Sigma-Aldrich Cat# A6730 
CI-976 Sigma-Aldrich Cat# C3743 
CAS 114289-47-3 









UB006 Professor Dolors 
Serra, University of 
Barcelona, Spain 
Makowski et al. 2017. 
Lipofectamine RNAiMAX ThemoFisher Scientific Cat# 13778075 
 
Critical Commercial Assays 
RNA extraction RNeasy kit Qiagen Cat# 74104 
iScript cDNA synthesis kit BioRad Cat# 1708891 
iTaq Universal SYBR Green Supermix BioRad Cat# 172-5124 
Proteome Profiler Human Phospho-Kinase Array Kit R&D systems Cat# ARY003C 
EnVision G/2 Doublestain System Rabbit/Mouse  Dako Cat# K536111-2 
Experimental Models: Cell Lines 
SK-N-BE(2) ATCC Cat# CRL-2271 
Human primary fibroblasts ATCC Cat# PCS-201-012 
IMR-32 ATCC Cat# CCL-127 
SK-N-AS ATCC Cat# CRL-2137 
SK-N-SH ATCC Cat# HTB-11 
SH-SY5Y ATCC Cat# CRL-2266 
KELLY ECACC Cat# 92110411 
SK-N-BE(2)shMYCN Professor Christer 
Einvik, Arctic 
University of Norway, 
Tromsö, Norway 
Henriksen et al. 2011 








TET-21/N Professor Manfred 
Shwab, DKFZ, 
Heidelberg, Germany 
Lutz et al. 1996 
TH-MYCN tumor spheres This paper Ribeiro et al. 2016 
 
LU-NB-2 Professor Daniel 
Bexell, Lund 
University, Sweden 
Persson et al. 2017 
LU-NB-3 Professor Daniel 
Bexell, Lund 
University, Sweden 
Persson et al. 2017 
Experimental Models: Organisms/Strains 



















siRNA against human FANS ThemoFisher Scientific Cat# s5032 
Negative control siRNA ThemoFisher Scientific Cat# 4390846 
Software and Algorithms 

















GraphPad Prism 6 GraphPad https://www.graphpa
d.com/scientific-
software/prism/ 












Adobe Illustrator CS6 Adobe www.adobe.com 
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